Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/42205
Tipo de documento
ArtigoDireito Autoral
Acesso aberto
Coleções
- ICTB - Artigos de Periódicos [40]
- IOC - Artigos de Periódicos [12747]
Metadata
Mostrar registro completo
THE POSSIBLE MANAGEMENT OF HYPERTENSIVE PATIENTS INFECTED WITH COVID-19 THROUGH THE USE OF ALISKIREN
Possible management
Hypertensive patients
Infection
Use of Aliskiren
Afiliação
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Celular. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Ciência e Tecnologia em Biomodelos. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Ciência e Tecnologia em Biomodelos. Rio de Janeiro, RJ, Brasil.
Resumo em Inglês
In late 2019, a novel corona virus (COVID-19) was identified in Wuhan, a city in the Hubei province of China. COVID-19 rapidly spread and led to an outbreak
in China and then became a global health emergency. Human pathogenic coronavirus bind to their target cells through angiotensin-converting enzyme 2 (ACE2).
The expression of ACE2 is substantially increased in hypertension patients and with type 1 or type 2 diabetes. Hypertension is also treated with ACE inhibitors and
ARBs, which results in an upregulation of ACE2.We therefore hypothesis that hypertension and diabetes treatment with ACE2-stimulating drugs increases the risk
of developing severe and fatal COVID-19. Therefore, we propose for COVID-19 patients to prevent ANG I and II formation by direct blockade of renin with the
specific inhibitor called Aliskiren. The aliskiren acts as a renin inhibitor, which blocks the conversion of angiotensinogen to ANG I. Hence, blood pressure is reduce
by decreasing the amount of ANG II to reach the AT1 receptor, thereby causing a decrease ACE2 released. Through the respective review, we hope to contribute to
the treatment of patients infected with COVID-19, especially hypertensive patients.
Palavras-chave em inglês
COVID-19Possible management
Hypertensive patients
Infection
Use of Aliskiren
Compartilhar